Holen Sie sich die Stockscreener-App
4.76
6.97%
0.31
Handel nachbörslich:
4.82
0.06
+1.26%
Schlusskurs vom Vortag:
$4.45
Offen:
$4.5
24-Stunden-Volumen:
55,871
Relative Volume:
0.31
Marktkapitalisierung:
$51.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.09M
KGV:
-2.6742
EPS:
-1.78
Netto-Cashflow:
$-17.24M
1W Leistung:
-7.39%
1M Leistung:
+29.35%
6M Leistung:
-1.45%
1J Leistung:
+19.90%
1-Tages-Spanne:
$4.46
$4.8618
1-Wochen-Bereich:
$4.2001
$5.2805
52-Wochen-Spanne:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
4.76 | 47.99M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - Business Wire
Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Rises By 109.5% - MarketBeat
Price momentum metrics for Lantern Pharma Inc. explainedHigh Confidence Strategy with Trend Alignment - Newser
Is Lantern Pharma Inc. meeting your algorithmic filter criteriaStable Profit Zone and Loss Control Analysis - Newser
What data driven models say about Lantern Pharma Inc.’s futureFree Trade Setups With Clear Risk Limits - Newser
Can volume confirm reversal in Lantern Pharma Inc.Alpha Stock Picks with Chart Confirmation - Newser
Automated trading signals detected on Lantern Pharma Inc.Free Entry Points For Growing Stocks - Newser
Os Therapies Incorporated shares rise 1.14% intraday after Lantern Pharma's subsidiary cleared IND application for GBM trial. - AInvest
Lantern Pharma Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule - citybuzz -
Lantern Pharma (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations - Barchart.com
Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Lantern Pharma Announces Release of Advanced AI Module for Blood-Brain Barrier Permeability Prediction - AI Insider
Nerdy Inc. shares rise 1.78% after-hours following Lantern Pharma's FDA clearance for GBM trial. - AInvest
How Lantern Pharma Inc. stock performs during market volatilityDaily Stock Forecast Powered by AI Tools - Newser
Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial - Barchart.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed - openPR.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Dnatrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Menafn
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | DNAtrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Barchart.com
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial | LTRN Stock News - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial - Business Wire
Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy - Barchart.com
Lantern Pharma completes Japanese enrolment for lung cancer drug trial - Mugglehead Magazine
Lantern Pharma schließt japanische Rekrutierung für Lungenkrebsmedikamentstudie ab - Mugglehead Magazine
Real Time Chart Alerts Flash Bullish on Lantern Pharma Inc.Swing Trade Plans Emphasize Risk Management - metal.it
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™ - 01net
Lantern Pharma Announces Public Release of AI Module for Blood-Brain Barrier Permeability Prediction - AInvest
Lantern Pharma Unveils PredictBBB.ai With 94% Accuracy, Revolutionizing CNS Drug Development Through Real-Time AI - 富途牛牛
How strong is Lantern Pharma Inc. company’s balance sheetNavigate market volatility with smart strategies - Jammu Links News
How does Lantern Pharma Inc. generate profit in a changing economyGame-changing returns - Jammu Links News
Is Lantern Pharma Inc. stock overvalued or undervaluedExceptional growth trajectory - Jammu Links News
What are analysts’ price targets for Lantern Pharma Inc. in the next 12 monthsUnlock your trading potential today - Jammu Links News
How volatile is Lantern Pharma Inc. stock compared to the marketAchieve rapid capital gains with smart investing - Jammu Links News
What makes Lantern Pharma Inc. stock price move sharplyRapid wealth multiplication - Jammu Links News
Is it the right time to buy Lantern Pharma Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
What is the dividend policy of Lantern Pharma Inc. stockStay ahead with advanced stock screening tools - Jammu Links News
Lantern Pharma Appoints Dr. Schalop to Board - MSN
Lantern Pharma Inc. Recovery Gathers Momentum on Chart SignalsWatchlist for Smart Swing Trading Updated - metal.it
What is Lantern Pharma Inc. company’s growth strategyBeginner Investor Report With Low Risk - Jammu Links News
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan - Yahoo Finance
Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan - Barchart.com
Lantern Pharma's Strategic Expansion in Japan: A Catalyst for Near-Term Stock Appreciation - AInvest
Lantern Pharma (LTRN) Concludes Phase 2 Trial Enrollment in Japa - GuruFocus
Lantern Pharma shares rise 8.23% premarket after completing targeted enrollment for lung cancer trial in Japan. - AInvest
Lantern Pharma completes Japanese enrollment in lung cancer trial By Investing.com - Investing.com Australia
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300 - Business Wire
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Trial in Japan for LP-300, Validates International Expansion Strategy. - AInvest
Short Interest Drops in Lantern Pharma Inc. After RallyEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Why Lantern Pharma Inc. stock attracts strong analyst attentionRisk Limited High Gain Trades - beatles.ru
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):